Retinalamin
Polypeptide complex from bovine retinal tissue — approved in Russia for age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa.
🔬 Mechanism of Action
Retinalamin is a polypeptide complex extracted from bovine retinal tissue following Khavinson's Cytomax methodology. It contains retina-specific short peptides that are proposed to modulate gene expression in retinal pigment epithelium (RPE) cells, photoreceptors, and Müller glia. The preparation supports RPE cell viability, reduces oxidative stress via upregulation of superoxide dismutase and catalase, improves retinal microcirculation, and modulates inflammatory cytokines in the retinal microenvironment. Approved in Russia for age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa — typically administered as parabulbar (periocular) or intramuscular injections in 10-day treatment courses.
Source: PMID: 15677927
📜Background & History
Retinalamin is a specialized ophthalmological Cytomax extract developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It is one of the few Khavinson preparations administered via the parabulbar route (injection into periocular fat), allowing more direct access to retinal tissues. Used clinically in Russia for degenerative retinal conditions, it represents the application of peptide bioregulation to ophthalmology.
🎯 Research Use Cases
- ✓Age-related macular degeneration
- ✓Diabetic retinopathy
- ✓Retinitis pigmentosa
- ✓Glaucoma support
💉 Dosing Protocol
| Typical Dose | 5 mg IM or parabulbar injection |
| Frequency | 1× daily for 10 days |
| Half-Life | ~2 hours |
| Common Vial Sizes | 5 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
Well-tolerated in Russian ophthalmological practice. Parabulbar injection requires trained ophthalmologist. IM route is less invasive but may have reduced local retinal bioavailability. Not approved in EU/US — evidence base is primarily Russian-language clinical literature.
⚡Interactions & Contraindications
Parabulbar injection requires trained ophthalmologist. No reported drug interactions with standard optic medications.
🔗Synergies & Common Stacks
Retinalamin (injectable extract) + Visoluten (oral capsule) = comprehensive eye health protocol combining systemic and targeted delivery.
Retinalamin + Normoftal target different aspects of ocular tissue health.